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Abstract 28 
Obese adipose tissue (AT) exhibits increased macrophage number. Pro-inflammatory CD16+ 29 
peripheral monocyte numbers are also reported to increase with obesity.  The current study was 30 
undertaken to simultaneously investigate obesity-associated changes in CD16+ monocytes and adipose 31 
tissue macrophages (ATM). In addition, a pilot randomised placebo controlled trial using the 32 
peroxisome proliferator-activated receptor (PPAR) agonists, pioglitazone and fenofibrate was 33 
performed to determine their effects on CD14+/CD16+ monocytes, ATM and cardiometabolic and 34 
adipose dysfunction indices. Obese glucose-tolerant men (n=32) were randomised to placebo, 35 
pioglitazone (30 mg/day) and fenofibrate (160 mg/day) for 12 weeks.  A blood sample was taken to 36 
assess levels of serum inflammatory markers and circulating CD14+/CD16+ monocyte levels via flow 37 
cytometry. A subcutaneous (sc) AT biopsy was performed to determine adipocyte cell surface and AT 38 
macrophage (ATM) number, the latter was determined via assessment of CD68 expression by 39 
immunohistochemisty (IHC) and real time PCR. SC AT mRNA expression of CCAAT enhancer-40 
binding protein β (CEBPβ), sterol regulatory element-binding protein 1c (SREBP1c), PPARγ2, 41 
insulin receptor substrate 1 (IRS-1), glucose transporter type 4 (GLUT 4) and tumour necrosis factor α 42 
(TNF-α) were also assessed.  Comparisons were made between obese and lean controls (n=16) at 43 
baseline, and pre- and post-PPAR agonist treatment. Obese individuals had significantly increased 44 
adipocyte cell surface, % CD14+/CD16+ monocyte numbers and ATM number (all p=0.0001). 45 
Additionally, serum TNF-α levels were significantly elevated (p=0.017) and adiponectin levels 46 
reduced (total: p=0.0001; high: p=0.022) with obesity.  ATM number and % of CD14+/CD16+ 47 
monocytes correlated significantly (P=0.05). Pioglitazone improved adiponectin levels significantly 48 
(p=0.0001), and resulted in the further significant enlargement of adipocytes (p=0.05), without effect 49 
on % CD14+/CD16+ or ATM number.  Pioglitazone treatment also significantly increased sc AT 50 
expression of CEBPβ mRNA. The finding that improvements in obesity-associated insulin resistance 51 
following pioglitazone were associated with increased adipocyte cell surface and systemic adiponectin 52 
levels, supports the centrality of AT to the cardiometabolic derangement underlying the development 53 
of T2D and CVD. 54 
55 
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Introduction 56 
It has been reported that in obesity adipose tissue (AT)  macrophage number increase, in addition to 57 
undergoing a phenotypic switch from  protective M2 to pro-inflammatory M1 [1-3]. Evidence is 58 
mounting to support the contention that paracrine interactions between AT macrophages (ATM) and 59 
adipocytes play a central role in initiating and maintaining obesity-associated adipose dysfunction [1-60 
4]. It has been speculated that AT dysfunction contributes to the systemic inflammatory status of 61 
obesity and, thus, may promote the development of type 2 diabetes (T2D) and cardiovascular disease 62 
(CVD).  Therefore, targeting the underlying inflammatory mechanisms may have therapeutic potential 63 
in the management of obesity and subsequent CVD risk.  64 
 65 
Excess energy intake results in impaired adipogenesis, enlargement of adipocytes and increased 66 
secretion of pro-inflammatory adipokines, in addition to a decreased production of the insulin 67 
sensitising adipokine, adiponectin [1]. Circulating levels of adiponectin have been considered a 68 
surrogate marker of adipose functionality and in terms of specific risk biomarkers for CVD and 69 
diabetes, a recent publication examining the contribution of different biological pathways to the 70 
development of type 2 diabetes concluded that adiponectin was the most important contributor, 71 
explaining one third of the risk [5].  Pro-inflammtory adipokines, which include TNF-α, interleukin 6 72 
(IL-6) and monocyte chemoattractant protein-1 (MCP-1), modulate insulin sensitivity, cardiovascular 73 
homeostasis, inflammation as well as adipose mass [6]. Large adipocytes release more saturated free 74 
fatty acids which can stimulate macrophages to increase TNF-α production via NF-ΚB activation 75 
[7,8]. In turn macrophage-derived TNF-α activates the adipocytes inducing further lipolysis and 76 
secretion of chemokines such as MCP-1 which promote the diapedesis of peripheral monocytes into 77 
the AT and differentiation into macrophages. The pro-inflammatory CD16+ peripheral monocytes are 78 
thought to drive the inflammatory processes associated with atherosclerosis.  A significant association 79 
between CD16+ monocytes and both obesity and subclinical atherosclerosis has been reported [9]. 80 
More recently it has been observed that weight loss can diminish this monocyte subpopulation [10]. 81 
 82 
Peroxisome proliferator-activated receptor (PPAR) ligands were developed to improve insulin 83 
sensitivity however they demonstrate additional effects on the arterial wall, which suggest that they 84 
also could reduce cardiovascular risk. Previously we have demonstrated that pioglitazone and 85 
fenofibrate treatment of obese, glucose tolerant men reduces inflammation, improves markers of 86 
endothelial function and reduces arterial stiffness [11].  Furthermore the improved insulin sensitivity 87 
observed with pioglitazone treatment was accompanied by increased adiponectin demonstrating the 88 
potential of PPAR agonists to reduce the incidence of premature CVD associated with obesity through 89 
effects on the arterial wall and AT.  Recent reports indicate that pioglitazone has direct effects on 90 
subcutaneous (sc) AT promoting adipogenesis in obese, non-diabetic, insulin-resistant subjects [12, 91 
13]. Fenofibrate has also been shown to reduce fat mass through increased β-oxidation in various 92 
animal models [14, 15], but information regarding the effects of fenofibrate in human sc AT is 93 
lacking.  94 
 95 
While previous investigations have investigated obesity-associated changes in ATM number or 96 
CD16+ monocytes, to date these monocyte/macrophage populations have not been examined within a 97 
single study.  Therefore, the current study was undertaken to simultaneously examine obesity-98 
associated changes in peripheral CD 14+/CD16+ monocytes and ATM in order to assess potential 99 
relationships between these monocyte/macrophage populations, and between these and 100 
cardiometabolic/adipose dysfunction indices in a normoglycaemic, but insulin resistant, obese 101 
population. Moreover, in order to investigate the effects of PPAR agonists, pioglitazone and 102 
fenofibrate on CD 14+/CD16+ monocytes, ATM number, adipocyte cell surface and sc AT gene 103 
expression, a pilot randomised placebo controlled clinical trial was conducted. 104 
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Methods  105 
Study design 106 
The protocol for the randomised placebo controlled trial was approved by Office for Research Ethics 107 
Committees Northern Ireland (reference number 06/NIR03/146) and clinical trial details were logged 108 
in the EudraCT database (reference number 2006-004296-35).  Clinical Trial Authorisation was 109 
obtained from the Medicines and Healthcare Products Regulatory Agency.  110 
 111 
Setting and participants 112 
Obese [body mass index (BMI)≥30 kg/m2], glucose tolerant males, aged 35-65 years and lean controls 113 
were recruited from the general population (including General Practice patients, hospital and 114 
university staff)  by clinical trial staff. All lean and obese participants attended the Regional Centre 115 
for Endocrinology and Diabetes at the Royal Victoria Hospital for assessment and gave written 116 
informed consent.  Exclusion criteria were as follows: smoker, clinical cardiac disease, clinical 117 
dyslipidaemia, plasma cholesterol >7 mmol/L, fasting triglycerides (TGs) >5 mmol/L, blood pressure 118 
>160/90 mmHg, diabetes/family history of diabetes, glucose intolerance, or use of hypertensive, 119 
cardiac, non-steroidal anti-inflammatory drugs or lipid-lowering therapies. 120 
Pre-treatment visit: All lean (n=16) and obese (n=37) participants attended hospital after an overnight 121 
fast for a medical history and examination, including weight, height and waist:hip ratio (WHR) 122 
determination. Blood pressure was measured at the right brachial artery using the OMRON HEM-123 
705CP automated sphygmomanometer (OMRON, Milton Keynes, Bucks, UK). A 75 g oral glucose 124 
tolerance test (OGTT) was performed with plasma glucose samples taken at 0, 30, 60, 120 and 180 125 
minutes to determine glucose tolerance and insulin sensitivity. The homeostatic model assessment of 126 
insulin resistance (HOMA) index was calculated using the following formula: fasting insulin (mU/L) 127 
x fasting glucose (mmol/L) /22.5. Blood was drawn and aliquoted for lipid profile, haemoglobin A1c 128 
(HbA1c), monocyte isolation, serum adiponectin and TNF-α. A sc fat biopsy was also obtained.  129 
Treatment phase: Obese subjects taking part in the pilot clinical trial (n=28) were randomised to 12 130 
weeks treatment with either fenofibrate (Supralip®, Fournier) 160 mg once per day, pioglitazone 131 
hydrochloride (ACTOS®, Takeda) 30 mg once per day or placebo. For safety purposes, liver function 132 
tests were also performed every 4 weeks.   133 
Post-treatment visit: Obese subjects randomised to 12 weeks treatment attended for a post-treatment 134 
assessment at which all pre-treatment assessment procedures were repeated. 135 
 136 
Biochemical and lipid assessment 137 
HbA1c was assessed by ion-exchange high-performance liquid chromatography on an Adams™       138 
HA-8160 automated analyser (Menarini Diagnostics, Wokingham, Berkshire, UK). Serum insulin was 139 
measured by immunoassay on an Abbott IMx analyser (Abbott Diagnostics, Maidenhead, Berkshire, 140 
UK). Fasting plasma glucose, total cholesterol (TC), HDL-cholesterol (HDL-C) and TGs were 141 
measured using slide based dry chemistry on a VITROS 950 analyser (Ortho-Clinical Diagnostics, 142 
Bucks, UK). LDL-cholesterol (LDL-C) was calculated using the Friedewald equation. 143 
 144 
Analysis of serum inflammatory markers 145 
Total and high adiponectin were analysed using a human multimeric adiponectin ELISA (ALPCO 146 
immunoassays, Newmarket, Suffolk, UK; intra-assay CV total 1.30%, high 2.04%;  inter-assay CV 147 
total 3.50%, high 2.50%). TNF-α was measured using the Quantikine® high sensitivity human TNF-α 148 
immunoassay kit (R&D systems, Abingdon, UK; intra-assay CV 3.67%; inter-assay CV 6.40%).  149 
 150 
Preparation and analysis of CD14+/CD16+ peripheral blood mononuclear cells 151 
Peripheral blood mononuclear cells (PBMCs) were isolated by Histopaque (density 1.077 g/L; ratio of 152 
blood to Histopaque, 1:1) (Sigma-Aldrich, Dorset, UK) and incubated for 30 min at 4°C with two 153 
fluorescently labelled monoclonal antibodies: FITC-conjugated anti-CD14 (Santa Cruz 154 
Biotechnology, Heidelberg, Germany) and PE-conjugated anti-CD16 (Santa Cruz Biotechnology). 155 
Cells were then washed in phosphate buffered saline (PBS), centrifuged for 10 min at 250 g and 156 
resuspended in PBS/4% paraformaldehyde (PFA) 4:1 (v/v). Fixed CD14+/CD16+ cells were analysed 157 
via flow cytometry (FACSCalibur) (Becton Dickinson, Oxford, UK). Monocytes were identified by 158 
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forward and side scatter properties. Fluorescence data were collected on 10,000 cells and analysed 159 
using CELLQUEST software (Becton Dickinson).  160 
 161 
Adipose analysis 162 
Subcutaneous fat biopsy:  Skin was firstly cleaned and anesthetized with 2 % xylocaine. A blunt 163 
dissection was then made and a small sample of sc AT (approximately 1 g) was removed from the 164 
periumbilical region using sterile forceps. Collected tissue was washed extensively in PBS and 165 
divided into 2 aliquots: i) an aliquot was formalin fixed and paraffin embedded; ii) an aliquot was 166 
added to RNAlater (Ambion, Warrington, UK), snap frozen and stored at –80°C until required. 167 
Adipocyte cell surface: Formalin fixed paraffin embedded sc AT sections (4 μm) were stained in 168 
haematoxylin and photographed in triplicate using an Olympus microscope and SPOT Advanced 169 
software (SPOT Imaging Solutions, Sterling Heights, Michigan, USA). Captured images were 170 
examined using Photoshop CS4 Extended software (Adobe Systems Incorporated, San Jose, USA). 171 
The magnetic lasso tool was used to outline adipocytes and from this the software calculated cell area 172 
in pixels. Pixels were converted manually to μm2 in excel using a scale conversion of 1 pixel=2.3543 173 
μm2 [11]. 174 
 175 
ATM assessment 176 
ATM content was assessed by both immunohistochemistry (IHC) staining for CD68  in formalin fixed 177 
paraffin embedded sections, and real time polymerase chain reaction (PCR) analysis of CD68  178 
messenger RNA (mRNA) expression, in recognition that this combinatorial approach largely 179 
overcomes the limitations of using either method in isolation [16].  Several studies have reported a 180 
strong correlation between results obtained via CD68 IHC (Mphi, fraction of CD68 expressing cells) 181 
and mRNA expression of CD68 when used to assess of AT macrophage number [16-18]. 182 
IHC analysis: Sections (4 μm) of formalin fixed paraffin embedded sc AT were mounted onto APES-183 
coated slides, dewaxed in xylene and incubated with a heated citrate buffer (100°C, 20 min) for 184 
antigen retrieval. An avidin/biotin blocking reagent [(Avidin/Biotin Blocking Kit; SP-2001) Vector 185 
Laboratories, Peterborough, England] was then applied to the sections, according to the 186 
manufacturer’s protocol, before being incubated with hydrogen peroxide for 5 min. Sections were 187 
covered with a CD68 PGM1 IgG3 Kappa primary antibody (N1576; Dako, Cambridgeshire, UK) and 188 
incubated for 20 min. Negative control sections were incubated in a universal negative control reagent 189 
(N1698; Dako). For staining and development of the sections, a DakoCytomation LSAB 2 System-190 
HRP Kit (K0673; Dako) was used, exactly according to the manufacturer’s instructions.  The number 191 
of CD68 positive cells were expressed as a percentage of the total number of cells counted per slide 192 
per subject. 193 
Real time PCR: Total RNA was extracted from frozen whole sc AT using the RNeasy® Lipid Tissue 194 
Midi Kit (Qiagen, Crawley, West Sussex, UK), exactly according to the manufacturers protocol. RNA 195 
quantity and purification was determined on a ND-1000 NanoDrop® spectrophotometer (Thermo 196 
Scientific, USA). Total RNA (100 ng) was reversed transcribed using the Transcriptor High Fidelity 197 
complementary DNA (cDNA) Synthesis Kit (Roche, Burgess Hill, West Sussex, UK), according to 198 
the manufacturer’s instructions and samples were stored at -20°C until required.   199 
Real-time PCR was performed using FastStart SYBR Green mastermix (Roche) on ABI Prism 7000 200 
sequence detection system (Applied Biosystems, Paisley, UK) programmed for universal cycling 201 
conditions (95°C for 10 min and 40 cycles of 95°C for 15 s and 60°C for 1 min) followed by melting 202 
curve analysis. Gene specific PCR primers were designed using the Primer Express software version 203 
1.5 (Applied Biosystems) and synthesized by Invitrogen Life Technologies. The primers used were as 204 
follows: CD68 (GenBank accession no. NM_001251; forward 5’-CCCCACGCAGCACAGTG-3’; 205 
reverse 5’-GATCTCGAAGGGATGCATTCTG-3’), CCAAT enhancer-binding protein β (CEBPβ) 206 
(GenBank accession no. NM_005194; forward 5’-GCCGCCGCCTGCCTTTAAATC-3’; reverse 5’-207 
GCCAAGCAGTCCGCCTCGTAG-3’), PPARγ2 (GenBank accession no. NM_015869; forward 5’-208 
GGCCAAGGCTTCATGACAAG-3’; reverse 5’-AAAAGGCTTTCGCAGGCTCT-3’), sterol 209 
regulatory element-binding protein 1c (SREBP1c) (GenBank accession no. NM_001005291; forward 210 
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5’-TGCAACACAGCAACCAGAAAC-3’; reverse 5’-TTGCTTTTGTGGACAGCAGTG-3’), glucose 211 
transporter type 4 (GLUT 4) (GenBank accession no. NM_001042; forward 5’- 212 
ATGTTGCGGAGGCTATGGG-3’; reverse 5’-GGAGGACCGCAAATAGAAGGA-3’), insulin 213 
receptor substrate 1 (IRS-1) (GenBank accession no. NM_005544; forward 5’-214 
TGAGGATTTAAGCGCCTATGC-3’; reverse 5’-TTGAGCTACTGACGGTCCTCTG-3’) and TNF-215 
α (GenBank accession no. NM_000594; forward 5’-ATCTTCTCGAACCCCGAGTGA-3’; reverse R 216 
5’-GGGTTTGCTACAACATGGGC-3’). PCR was performed in triplicate with cycle threshold (Ct) 217 
values calculated automatically using the Sequence detection software version 1.2.3 (Applied 218 
Biosystems). The house keeping genes used were glyceraldehyde 3-phosphate dehydrogenase 219 
(GAPDH) (GenBank accession no. NM_002046; forward 5’-ATCCATGACAACTTTGGTATCGTG-220 
3’; reverse 5’-GGCATGGACTGTGGTCATGAG-3’), ribosomal protein large P 0 (RPLP0) 221 
(GenBank accession no. NM_001002; forward 5’-GGCGTCCTCGTGGAAGTGACAT-3’; reverse 222 
5’-CAGGGATTGCCACGCAGGGT-3’) and 18S (GenBank accession no. NR_003286; forward 5’-223 
CGGAGGTTCGAAGACGATCA-3’; reverse 5’-GGCATCGTTTATGGTCGGAA-3’). These 224 
housekeeping genes have been used in previous gene expression analyses in AT and, in agreement 225 
with previous studies [19-21], in the current study expression of none of the three housekeeping genes 226 
were found to be altered by either obesity or treatment. Individual subject gene expression was 227 
normalised to the relevant housekeeping gene [delta Ct (ΔCt)].  For comparison of lean vs obese gene 228 
expression, the obese group mean fold change relative to the lean control group was calculated using 229 
the group mean ΔCt values in the formula 2^-ΔΔCt.  Differences between lean and obese ΔCt values 230 
were analysed using independent t-tests and a p value less than or equal to 0.05 was considered 231 
statistically significant.  For pre- vs post-treatment comparisons, individual obese subject post-232 
treatment mRNA expression was calculated as a fold change relative to pre-treatment for each 233 
participant using the formula 2^-ΔΔCt.  Differences between pre- and post-treatment ΔCt values were 234 
analysed using paired t-tests. Treatment change (post – pre) was compared with placebo change (post 235 
– pre) by independent t-test. A p value less than or equal to 0.05 was considered statistically 236 
significant. 237 
 238 
Statistical analysis  239 
Statistical analyses were carried out using SPSS software version 18.0. Lean and obese groups were 240 
compared at baseline by independent t-test; obese treated groups were analysed by calculating the 241 
change (post - pre) and comparing with placebo change (post - pre) also using independent t-tests. 242 
Correlations between continuous variables were assessed by Pearson’s coefficients for correlations. 243 
Logistic regression analysis was used to determine if existing correlations remained once BMI was 244 
added to the model. 245 
Individual subject ΔCt values were used to assess correlations between mRNA expression and 246 
continuous variables and, as higher ΔCt values reflect lower mRNA expression, negative correlations 247 
do not represent inverse relationships between variables. Variables not normally distributed were log 248 
transformed to natural logarithms prior to analysis to allow for parametric testing. Serum results were 249 
obtained from fasting variables and all results are presented as mean ± standard deviation (S.D). A p 250 
value less than or equal to 0.05 was considered statistically significant. 251 
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Results  252 
Anthropometric and biochemical characteristics of study participants  253 
Baseline anthropometric and biochemical characteristics of study participants are shown in Table 1. 254 
As expected, both BMI and WHR were significantly increased in the obese group relative to the lean 255 
group. Additionally, the lean group displayed significantly lower systolic blood pressure (SBP) and 256 
diastolic blood pressure (DBP) compared with baseline levels in the obese group. The obese group 257 
displayed significantly greater glucose levels at baseline. Nonetheless, levels after 120 minutes of the 258 
OGTT were not significantly different between groups, indicating that despite obesity, participants 259 
who entered the study had normal glucose tolerance. In support of this, there was no significant 260 
difference in HbA1c levels between the groups. There were two surrogate markers of insulin resistance 261 
used in the study: fasting insulin levels and HOMA index. Both parameters were significantly lower 262 
in the lean participants compared to the obese, signifying insulin resistance within the obese group. 263 
Severe dyslipidaemia was an exclusion criterion in the study; this would indicate why TC and LDL-C 264 
were similar between the two groups. In keeping with dyslipidaemic features associated with obesity, 265 
HDL-C was significantly higher and TGs lower in the lean individuals relative to the obese. 266 
Additionally, both the TC/HDL-C ratio and LDL-C/HDL-C ratio were significantly increased with 267 
obesity. 268 
 269 
Cytokine and peripheral monocyte levels and adipocyte cell surface assessment 270 
As expected, baseline levels of TNF-α were significantly higher in the obese participants compared to 271 
the lean (Table 2). Additionally, levels of total and high adiponectin were significantly reduced with 272 
obesity (Table 2). There was no significant difference in the high to total adiponectin ratio between 273 
the two groups.  274 
The obese group exhibited a significantly higher percentage of peripheral CD14+/CD16+ monocytes 275 
[Lean vs. Obese (%); 13.9±4.5 vs. 21.1±5.6, p<0.0001] (Figure 1b) and greater adipocyte cell surface 276 
[Lean vs. Obese (μm2); 1748±488 vs. 3334±538, p<0.0001] (Figure 1c) compared to their lean 277 
counterparts. 278 
 279 
ATM assessment 280 
The percentage of CD68 expressing cells within sc AT [Lean vs. Obese (%); 0.96±0.69 vs. 3.95±3.97, 281 
p<0.0001] was significantly elevated with obesity (Figure 2a). In parallel, CD68 mRNA expression 282 
followed a similar trend, with a 1.62 fold increase in the obese group relative to the lean group (Figure 283 
2b). 284 
 285 
Adipose tissue gene expression analysis 286 
The observed obesity-associated increases in circulating TNF-α levels were reflected in a significant 287 
increase in sc adipose tissue expression of this cytokine (Figure 3).  Expression of SREBP1c, CEBPβ, 288 
GLUT 4 and IRS-1 were all lower in obese vs lean adipose tissue, however, only the latter was 289 
significant (Figure 3).  Expression of PPAR2 was similar between lean and obese adipose tissue.   290 
 291 
Correlations between adipose markers, peripheral monocytes and CVD risk factors 292 
In agreement with the observation that obesity-associated increases in % of CD68 cells within AT 293 
(Figure 2a), BMI and WHR demonstrated positive correlations with % of CD68 expressing cells in sc 294 
AT (r=0.595, p=0.001, and r=0.429, p=0.023, respectively). 295 
As can be seen in Figure 4a, adipocyte cell surface correlated significantly with BMI,  % of CD68 296 
expressing cells in sc AT and  % of peripheral CD14+/CD16+ monocytes.  In addition, adipocyte cell 297 
surface correlated significantly with markers of insulin resistance: fasting insulin and HOMA index 298 
(Figure 4b).  Adipocyte cell surface also correlated significantly with both circulating TNF-α 299 
(r=0.455, p=0.008) and adipose tissue TNF-α mRNA levels (ΔCt r= 0.371, p=0.048), as well as 300 
being negatively correlated with total adiponectin (r= 0.411, p=0.017).  Only the correlation between 301 
adipocyte cell surface and % of CD68 expressing AT cells remained significant (p=0.014) after 302 
adjusting for BMI. 303 
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The percentage of CD68 expressing cells in sc AT and % of peripheral CD14+/CD16+ monocytes also 304 
demonstrated a significant correlation (Figure 4c); this was lost upon adjusting for BMI. The 305 
percentage of CD14+/CD16+ monocytes also showed a positive correlation with fasting insulin 306 
(r=0.378, p=0.048) and HOMA index (r=0.422, p=0.023), and a negative correlation with total 307 
adiponectin (r= 0.428, p=0.007), as well as high adiponectin (r= 0.362, p=0.025). Likewise, the 308 
percentage of CD68 expressing AT cells negatively correlated with total ( 0.578, p=0.001) and high 309 
adiponectin (r= 0.460, p=0.012). Again, correlations between CD14+/CD16+ monocytes and indices 310 
of insulin resistance and circulating levels of adiponectin isoforms became non-significant when 311 
adjusted for BMI, as did correlations between % of CD68 expressing AT cells and adiponectin. 312 
 313 
The effects of pioglitazone and fenofibrate on anthropometric and biochemical characteristics  314 
The effects of pioglitazone and fenofibrate on anthropometric and biochemical characteristics are 315 
shown in Table 3. Fasting insulin levels and HOMA index both improved significantly following 316 
pioglitazone treatment, demonstrating its ability to ameliorate obesity associated insulin resistance. As 317 
expected, fenofibrate exhibited its lipid-lowering effects by significantly reducing levels of TC, LDL-318 
C and TG, and improving the TC/HDL-C ratio and the LDL-C/HDL-C ratio. In addition, pioglitazone 319 
significantly enhanced HDL-C levels and had similar positive effects to fenofibrate on the TC/HDL-C 320 
ratio and the LDL-C/HDL-C ratio. 321 
 322 
The effects of pioglitazone and fenofibrate on adiponectin, adipocyte cell surface, ATM and 323 
peripheral monocyte numbers 324 
With respect to adiponectin, pioglitazone augmented levels of total [Pre vs. Post (μg/mL); 5.5±1.4 vs. 325 
10.4±5.7, p<0.0001] and high adiponectin [Pre vs. Post (μg/mL); 2.8±1.1 vs. 6.9±4.6, p<0.0001], and 326 
additionally, pioglitazone treatment improved the high to total adiponectin ratio (Pre vs. Post; 327 
0.49±0.09 vs. 0.62±0.11, p<0.0001). 328 
Neither pioglitazone nor fenofibrate treatment resulted in any significant changes in CD68 mRNA 329 
expression or the percentage of CD68 expressing cells within AT, nor did either treatment have any 330 
effect on the percentage of peripheral CD14+/CD16+ monocytes. Following pioglitazone treatment 331 
there was, however, a significant increase in adipocyte cell surface [Pre vs. Post (μm2); 3330±712 vs. 332 
3655±712, p=0.05]. 333 
 334 
The effects of pioglitazone and fenofibrate on adipose tissue gene expression 335 
Fenofibrate was without effect on the expression levels of any of the genes examined.  Pioglitazone 336 
significantly increased expression of CEBPβ (Figure 5; 4.26 fold). Pioglitazone treatment also 337 
resulted in increased expression of SREBP1c, PPAR2, GLUT 4, and IRS-1, albeit that none of these 338 
increases reached significance (Figure 5).  339 
Following pioglitazone treatment, CEBPβ expression exhibited significant positive correlations with 340 
IRS-1(r=0.979, p<0.0001) and SREBP1c (r=0.976, p<0.0001) mRNA levels, and a significant 341 
negative correlation with CD68(r= 0.822, p=0.045) mRNA expression.      342 
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Discussion 343 
Using a cohort of lean and obese glucose tolerant subjects this study is the first to simultaneously 344 
investigate obesity-associated changes in both peripheral blood CD14+/CD16+ monocytes and ATM.  345 
The results obtained indicate that obesity is associated with increased peripheral CD14+/CD16+ 346 
monocyte and sc ATM number, as well as increased sc adipocyte cell surface, reduced circulating 347 
adiponectin levels and lower sc AT expression of genes involved in macrophage phenotype, 348 
adipogenesis and glucose metabolism.  Moreover, pioglitazone treatment was found to result in 349 
significant improvements in insulin resistance and lipid profile, changes which occurred in parallel 350 
with significant increases in sc AT expression of CEBPβ mRNA, adipocyte cell surface and 351 
adiponectin levels. Taken together these results indicate that obesity-associated changes in 352 
CD14+/CD16+ monocyte levels and adipose function (as reflected in reduced systemic levels of 353 
adiponectin) are evident prior to the presence of impaired glucose tolerance, and that therapeutic 354 
interventions with the ability to target the latter may prove beneficial in reducing CVD risk and the 355 
development of T2D. 356 
Prediabetic individuals are defined as those with impaired glucose tolerance (2hr glucose 140-199 357 
mg/dL [7.8-11.0 mmol/L]) or impaired fasting glucose (fasting glucose concentration 110-125 mg/dL 358 
[5.6-6.9 mmol/L]) or an HbA1c of 5.7-6.4% [22]. A strength of the current study is that the obese 359 
subjects recruited did not have impaired glucose tolerance (2hr glucose 6.4±1.0 mmol/L; fasting 360 
glucose concentration 5.3±0.4 mmol/L; HbA1c 5.3±0.3%), thereby, enabling obesity-associated 361 
changes in primary and secondary endpoints to be investigated and the impact of PPAR agonist 362 
treatment on these endpoints to be evaluated.  Cardioprotective strategies, including lifestyle 363 
modification, have been shown to be most effective in averting or delaying the onset of diabetes when 364 
administered at this early stage in the hyperglycaemia/diabetes continuum [23].  The current study has 365 
provided evidence that preventative strategies are also effective when administered prior to the 366 
development of impaired glucose tolerance. 367 
Subcutaneous and visceral ATM number increase in obesity and evidence is accumulating that ATM 368 
are responsible for potentiating the chronic inflammatory processes of obesity [1, 2].  The origin of 369 
ATM remains to be fully elucidated, it has been reported that these arise from adipokine-dependent 370 
extravasated peripheral blood monocytes and evidence has also been presented that multi-potent 371 
adipocyte stem cells and pre-adipocytes can differentiate into macrophages [24, 25]. Both sc and 372 
visceral ATM number have been reported to correlate with clinical parameters of obesity and its co-373 
morbidities [18].  The results of the current study concur with previous reports, the percentage of 374 
CD68 expressing cells within AT was significantly elevated in obesity, while CD68 mRNA 375 
expression followed a similar trend. Moreover, BMI and WHR demonstrated positive correlations 376 
with the percentage of CD68 expressing cells in sc AT.  The percentage of CD68 expressing cells also 377 
negatively correlated with total and high adiponectin levels, indicating that ATM infiltration is 378 
associated with reduced adipocyte function.  Adipocyte enlargement is a strong, direct predictor of 379 
ATM recruitment and accumulation [26]. Macrophages have been detected in the sc and visceral AT 380 
of obese patients, in which they surround the dead adipocyte in a crown-like arrangement [27].  Given 381 
the evidence that adipocyte hypertrophy is a potential stimulus for ATM infiltration, it is of interest 382 
that, in the current study, adipocyte cell surface correlated significantly with both % of CD68 383 
expressing cells in sc AT and % of peripheral CD14+/CD16+ monocytes.  Given the observed obesity-384 
associated increases in the CD14+/CD16+ peripheral monocyte population, the significant correlation 385 
between % of CD68 expressing cells in sc AT and % of peripheral CD14+/CD16+ monocytes, and the 386 
evidence supporting a role for this population in vascular inflammation, it is tempting to speculate that 387 
these represent a source of the increased ATM number in sc AT, however, clearly this is an area that 388 
requires further analysis. 389 
The observation in the current study that pioglitazone and fenofibrate normalised obesity-associated 390 
insulin resistance and/or dyslipidaemia is as would be expected, indeed, in an earlier study similar 391 
results were reported by our group [11].  The observation that pioglitazone achieved this without 392 
significantly changing  % of peripheral CD14+/CD16+ monocytes or ATM number, but by 393 
significantly increasing adipocyte cell surface and improving adipocyte function  is a novel one.   394 
Clinical Science Immediate Publication. Published on 06 Feb 2012 as manuscript CS20110662
TH
IS
 IS
 N
O
T 
TH
E 
VE
RS
IO
N 
O
F 
RE
CO
RD
 - 
se
e 
do
i:1
0.
10
42
/C
S2
01
10
66
2
Ac
ce
pte
d M
a
us
cri
pt
Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
© 2012 The Authors Journal compilation © 2012 Portland Press Limited
10 
 
Taken together, these results suggest a model whereby modulation of adipocyte function, in the 395 
absence of effects on CD14+/CD16+ monocyte expansion or ATM number, results in cardioprotective 396 
outcomes.  While Di Gregorio and co workers [28] have reported a decrease in ATM following 397 
pioglitazone treatment, their cohort received a higher dose than used in the current trial (45 mg/day), 398 
moreover, their subjects had impaired glucose tolerance and were mixed gender.  Hammarstedt and 399 
co-workers have reported that 3 week treatment with a similar dose of pioglitazone in overweight, 400 
insulin resistant, glucose tolerant subjects had no effect on adipocyte cell surface, or indeed, in 401 
agreement with the results of the current study, adipose macrophage infiltration markers [29]. In 402 
contrast to the current study, however, short term pioglitazone treatment was found to be without 403 
effect on lipid levels [29]. PPAR agonists are reported to promote free fatty acid uptake and storage 404 
in adipocytes, thereby preventing lipotoxic trauma to liver and muscle and ameliorating insulin 405 
resistance.  In support of this, pioglitazone has been demonstrated to increase sc adipose mass [30].  406 
Moreover, it has been reported that congenital adrenal hyperplasia-associated insulin resistance was 407 
improved by pioglitazone treatment, and that this improvement in insulin sensitivity was associated 408 
with enlargement of sc adipocytes [12].   409 
A further novel finding of the current study is that, following pioglitazone treatment, sc AT CEBPβ 410 
expression was significantly increased.  Expression of CEBPβ, SREBP1c, GLUT 4 and IRS-1 were 411 
all lower in obese vs lean sc AT, the latter being significantly reduced.  These results are in keeping 412 
with an obesity-associated impairment in adipogenesis [1].   CEBPβ has been recently identified as a 413 
playing a central role in PPAR-mediated gene regulation in both adipocytes and macrophages, two 414 
cell types which predominate in obese sc AT [31, 32].  In addition, evidence has been presented that 415 
CEBPβ plays a non-PPAR-dependent role in mitotic clonal expansion during adipogenesis [33].   416 
The observation that pioglitazone upregulates CEBPβ is interesting given the central role of this 417 
transcription factor in adipogenesis and macrophage polarisation, and provides evidence that 418 
pioglitazone, in addition to increasing the function/size of mature adipocytes, promotes adipogenesis 419 
and may facilitate macrophage polarisation to the alternative, anti-inflammatory phenotype. It will be 420 
of interest in future studies to determine if pioglitazone-dependent  CEBPβ upregulation is reflected in 421 
increased protein levels of this transcription factor and whether this is associated with an increase in 422 
anti-inflammatory, and a decrease in proinflammatory, cytokine expression, as demonstrated in our 423 
previous study [11].  Pioglitazone treatment also resulted in increased, albeit non-significant, sc 424 
adipose expression of SREBP1c, PPAR2, GLUT 4, and IRS-1.  These results are in broad agreement 425 
with the findings of Hammarstedt et al [29], and further support a model whereby pioglitazone 426 
treatment facilitates adipocyte terminal differentiation.  427 
In conclusion, the current study has found evidence that increased adipocyte cell surface, expansion of 428 
the CD14+/CD16+ monocyte population and ATM number, and compromised AT function occurs in 429 
obese individuals prior to the development of impaired glucose tolerance. Further, significant 430 
associations between adipocyte cell surface and increased peripheral monocyte and ATM numbers 431 
support the role of adipocyte enlargement as an initiating stimulus in adipose 432 
inflammation/dysfunction.  The finding that improvements in obesity-associated insulin resistance 433 
following pioglitazone were associated with increased adipocyte cell surface and systemic adiponectin 434 
levels, supports the centrality of AT to the cardiometabolic derangement underlying the development 435 
of T2D and CVD. 436 
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Table 1 Anthropometric and biochemical characteristics of study participants at baseline 
Data are expressed as means±SD. Lean vs. obese groups were compared at baseline using 
independent t-tests. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristics Lean controls 
(n=16) 
Obese 
 (n=37) 
Differences in Means  
(95% CI) 
p value 
Age (years) 50±7 47 ± 7 4 (−0.09, 7.83) ns 
BMI (kg/m2) 23.9±1.4 35.0±4.0 −11.1 (−12.57, −9.57) <0.0001 
WHR 0.88±0.10 1.01±0.05 −0.12 (−0.17, −0.08) <0.0001 
SBP (mmHg) 117±9 129±12 −12 (−18.09, −4.98) 0.001 
DBP (mmHg) 74±7 82 ± 8 −8 (−12.53, −3.62) 0.001 
Fasting glucose (mmol/L) 5.1±0.4 5.3±0.4 −0.2 (−0.45, −0.002) 0.047 
2hr OGTT (mmol/L) 5.8±1.3 6.4±1.0 −0.6 (−1.25, 0.07) ns 
Fasting insulin (mU/l) 6.6±3.0 12.9±4.9 −6.3 (−8.90, −3.77) <0.0001 
HOMA index 1.4±0.6 3.2±1.4 −1.7 (−2.36, −1.10) <0.0001 
HbA1c (%) 5.2±0.2 5.3±0.3 −0.1 (−0.31, 0.09) ns 
TC (mmol/L) 5.0±0.8 5.3±0.6 −0.4 (−0.78, 0.07) ns 
LDL-C (mmol/L) 3.1±0.9 3.4±0.5 −0.3 (−0.79, 0.19) ns 
HDL-C (mmol/L) 1.46±0.27 1.22±0.24 0.24 (0.09, 0.39) 0.002 
TG (mmol/L) 
TC/HDL-C ratio 
LDL-C/HDL-C ratio 
1.00±0.40 
3.55±1.14 
2.24±0.98 
1.60±0.64 
4.45±0.73 
2.82±0.55 
−0.60 (−0.95, −0.25) 
−0.89 (−1.54, −0.25) 
−0.58 (−1.13, −0.04) 
0.001 
0.009 
0.038 
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Table 2 Serum levels of inflammatory markers of study participants at baseline 
Data are expressed as means±SD. Lean vs. obese groups were compared at baseline using 
independent t-tests. 
 
 
 
 
 
 
 
 
Inflammatory  
markers 
Lean controls 
(n=15) 
Obese 
 (n=37) 
Differences in Means  
(95% CI) 
p value 
TNF-α (pg/mL) 1.62±0.36 2.14±0.91 −0.53 (−1.01, −0.04) 0.017 
Total Adiponectin (µg/mL) 10.5±4.5 6.3±2.1 4.2 (1.59, 6.74) <0.0001 
High Adiponectin (µg/mL) 4.6±2.6 3.1±1.4 1.5 (0.01, 3.04) 0.022 
High/Total Adiponectin ratio 0.42±0.10 0.47±0.11 −0.05 (−0.11, 0.02) ns 
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Figure 1  Baseline analysis of CD14+CD16+ peripheral monocyte populations and adipocyte cell 
surface in lean and obese groups at baseline. Representative scatter dot plots showing 
CD14+CD16+ peripheral monocyte populations in lean and obese groups at baseline.   
Peripheral blood mononuclear cells were isolated by Histopaque and labelled with Fluorescein 
Isothiocyanate (FITC)-conjugated anti-CD14 and Phycoerythrin (PE)-conjugated anti-CD16. 
Fixed monocytes were identified by forward and side scatter properties. Fluorescence data were 
collected on 10,000 cells and analysed using CellQuest Pro software.  The percentage of 
CD14+CD16+ cells was calculated by combining the top left and right quadrants of the gated 
monocyte population (a). Mean percentage of peripheral CD14+/CD16+ monocytes (b), and 
mean adipocyte cell surface (μm2) (c) in lean (n=9-15) and obese (n=23-25) groups at baseline 
Error bars indicate S.D. Lean vs. obese groups were compared at baseline using independent t-tests: 
*p<0.05. 
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Figure 2 Comparison of mean percentage (±S.D) of CD68 expressing AT cells (a), and mean 
CD68 mRNA expression (b) in lean (n=7-13) versus obese (n=24-28) groups 
Individual subject CD68 mRNA expression was normalised to the housekeeping gene GAPDH using 
the formula ΔCt and the mean fold change relative to the lean control group calculated using the 
formula 2^-ΔΔCt (b). Data shown as group mean fold change and statistical analyses were performed on 
the individual ΔCt values. Differences between lean and obese groups at baseline were analysed using 
independent t-tests: *p<0.05. 
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Figure 3 Comparison of adipose gene expression in lean (n=12) versus obese (n=29) groups 
Individual subject IRS-1 and TNF-α mRNA expression was normalised to the housekeeping gene 
RPLP0 using the formula ΔCt and the mean fold change relative to the lean control group calculated 
using the formula 2^-ΔΔCt. Data shown as group mean fold change and statistical analyses were 
performed on the individual ΔCt values. Differences between lean and obese groups at baseline were 
analysed using independent t-tests: *p<0.05.   
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Figure 4 Correlations between adipocyte cell surface (μm2) and BMI, % of CD68 expressing cells and % of peripheral CD14+/CD16+ monocytes (a); 
correlations between adipocyte cell surface (μm2) and fasting insulin (mU/L) and HOMA index (b); correlation between % of CD68 expressing cells 
and % of peripheral CD14+/CD16+ monocytes (c);   
Correlations between continuous variables were assessed by Pearson’s coefficients for correlations. 
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Table 3 Anthropometric and biochemical characteristics of obese participants pre and post treatment  
Data are expressed as a mean ± SD. Obese treated groups were analysed by calculating change (post – pre) and comparing with placebo change (post – pre) 
using independent t-test: *p<0.05; †p<0.01. 
 
 
 Pioglitazone 
(n = 6-8) 
Fenofibrate 
 (n = 7-11) 
Placebo 
(n = 5-9) 
Characteristics Pre Post Mean % 
change 
Pre Post Mean % 
change 
Pre Post Mean % 
change 
BMI (kg/m2) 36.6±3.8 36.5±3.8 0 % 34.6±4.7 35.0±5.7 1 % 34.1±3.7 34.7±3.6 2 % 
WHR 1.02±0.05 1.01±0.05 -1 % 1.02±0.08 1.00±0.06 -2 % 0.97±0.03 0.97±0.05 0 % 
SBP (mmHg) 137±10 136±15 -1 % 126±8 119±9 -5 % 130±14 125±15 -4 % 
DBP (mmHg) 85±8 88±8 4 % 79±10 80±6 3 % 82±4 81±6 -2 % 
Fasting glucose (mmol/L) 5.1±0.4 5.1±0.2 0 % 5.4±0.3 5.1±0.4 -5 % 5.3±0.5 5.3±0.4 1 % 
2hr glucose (mmol/L) 6.2±0.7 5.9±1.3 -3 % 6.4±1.0 6.3±1.1 -1 % 6.8±1.3 6.7±1.4 2 % 
Fasting insulin (mU/l) 15.6±5.1 12.0±2.9* -16 % 13.0±5.1 14.4±8.2 9 % 9.9±3.4 12.5±5.7 25 % 
HOMA index 3.6±1.4 2.7±0.7* -15 % 3.2±1.6 3.2±1.7 2 % 2.4±1.0 3.0±1.4 27 % 
HbA1c (%) 5.2±0.2 5.2±0.2 0 % 5.4±0.3 5.3±0.2 -1 % 5.3±0.3 5.3±0.3 1 % 
TC (mmol/L) 4.9±0.4 4.9±0.8 -1 % 5.5±0.7 4.8±0.6* -13 % 5.3±0.8 5.3±0.5 1 % 
LDL-C (mmol/L) 3.1±0.4 3.0±0.9 -5 % 3.7±0.6 3.1±0.6* -14 % 3.1±0.5 3.3±0.4 9 % 
HDL-C (mmol/L) 1.15±0.22 1.19±0.20* 5 % 1.28±0.23 1.22±0.23 -4 % 1.26±0.35 1.14±0.30 -10 % 
TG (mmol/L) 
TC/HDL-C ratio 
LDL-C/HDL-C ratio 
1.48±0.39 
4.43±0.91 
2.81±0.72 
1.51±0.85 
4.20±1.00* 
2.59±1.00* 
7 % 
-5 % 
-9 % 
1.31±0.42 
4.40±0.69 
2.91±0.49 
1.02±0.39†  
4.04±0.97† 
2.64±0.79* 
-21 % 
-8 % 
-9 % 
2.01±0.83 
4.38±0.77 
2.50±0.42 
2.35±1.37 
4.90±0.99 
2.94±0.67 
13 % 
12 % 
18 % 
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Figure 5 Comparison of adipose gene expression in obese (n=7) subjects pre- and post-
pioglitazone treatment 
Post-treatment mRNA expression was calculated as a fold change relative to pre-treatment using the 
formula 2^-ΔΔCt. Data shown as mean fold change (±S.D) and statistical analyses were performed on 
the individual ΔCt values. Pioglitazone change (post – pre) was compared with placebo change (post 
– pre) using independent t-tests: *p<0.05. 
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